Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.50 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | KDM5A | P29375 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19546069 | 0.96 | CASP2 (0.52) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL889191 | 0.94 | DNM1 (0.49) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL19841954 | 0.92 | DNM1 (0.45) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL14478307 | 0.92 | DNM1 (0.49) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL19681637 | 0.91 | DNM1 (0.56) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL24412966 | 0.91 | CASP2 (0.63) | DNM1FAAHCASP2NAAAICMT | |
| SCHEMBL20305887 | 0.89 | CASP2 (0.67) | DNM1FAAHCASP2NAAAICMT | |
| SCHEMBL20305888 | 0.89 | CASP2 (0.67) | DNM1FAAHCASP2NAAAICMT | |
| SCHEMBL889318 | 0.89 | CASP2 (0.67) | DNM1FAAHCASP2NAAAICMT | |
| SCHEMBL889136 | 0.88 | MCL1 (0.48) | DNM1FAAHCASP2CNR1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016050210-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | 厦门赛诺邦格生物科技有限公司 | 2016-04-07 | — | — | WO | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | DNM1 4279/4885FAAH 858/4885CASP2 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.